[关键词]
[摘要]
目的 探讨甘草酸二铵肠溶胶囊联合恩替卡韦分散片治疗慢性乙型肝炎的临床疗效。方法 选择2019年2月—2020年5月在河南大学淮河医院就诊治疗的82例慢性乙型肝炎患者,按照随机数字表法将所有患者分为对照组和治疗组,每组各41例。对照组口服恩替卡韦分散片,0.5 mg/次,1次/d。治疗组患者在对照组治疗的基础上口服甘草酸二铵肠溶胶囊,150 mg/次,3次/d。两组患者连续治疗6个月。观察两组患者临床疗效,比较两组的肝功能指标、肝纤维化指标和血清因子指标。结果 治疗后,治疗组的总有效率95.12%,显著高于对照组的85.37%,组间差异有显著性(P<0.05)。治疗后,两组患者丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)水平与同组治疗前数据相比均显著降低,差异具有显著性(P<0.05);且治疗组患者ALT、AST、TBIL水平均明显低于对照组,组间比较有差异(P<0.05)。治疗后,两组患者透明质酸(HA)、黏连蛋白(LN)、Ⅲ型前胶原(PCⅢ)水平与同组治疗前数据相比较均显著降低(P<0.05);且治疗组患者HA、LN、PCⅢ水平均明显低于对照组,组间比较有差异(P<0.05)。治疗后,两组患者血清丙二醛(MDA)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)水平与同组治疗前数据相比较均明显降低,差异有统计学意义(P<0.05),且治疗组患者血清MDA、IL-6、hs-CRP水平均明显低于对照组,组间比较有差异(P<0.05)。结论 甘草酸二铵肠溶胶囊联合恩替卡韦分散片治疗慢性乙型肝炎具有较好的临床疗效,可改善肝功能,抑制肝纤维化,降低患者的血清因子水平,值得临床上借鉴。
[Key word]
[Abstract]
Objective To study the effects of Diammonium Glycyrrhizinate Enteric-coated Capsules combined with Entecavir Dispersible Tablets in treatment of chronic hepatitis B. Methods Patients (82 cases) with chronic hepatitis B in Huaihe Hospital of Henan University from February 2019 to May 2020 were divided into control and treatment groups according to the random number table method, and each group had 41 cases. Patients in the control group were po administered with Entecavir Dispersible Tablets, 0.5 mg/time, once daily. Patients in the treatment group were po administered with Diammonium Glycyrrhizinate Enteric-coated Capsules on the basis of the control group, 150 mg/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and liver function indexes, liver fibrosis indexes, and serum factor indexes in two groups were compared. Results After treatment, the total effective rate of the treatment group was 95.12%, which was significantly higher than 85.37% of the control group (P < 0.05). After treatment, the levels of ALT, AST, and TBIL in two groups were significantly lower than those before treatment (P < 0.05), and the levels of ALT, AST, and TBIL in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of HA, LN, and PCⅢ in two groups were significantly lower than those before treatment (P < 0.05), and the levels of HA, LN, and PCⅢ in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the serum levels of MDA, IL-6, and hs-CRP in two groups were significantly lower than those before treatment in the same group (P < 0.05), and the serum levels of MDA, IL-6, and hs-CRP in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Diammonium Glycyrrhizinate Enteric-coated Capsules combined with Entecavir Dispersible Tablets has clinical curative effect in treatment of chronic hepatitis B, can improve liver function, inhibit liver fibrosis and reduce the serum factor level of patients, which is worthy of clinical reference.
[中图分类号]
R975
[基金项目]
国家自然科学基金资助项目(81700187)